- Home
- GTE vs IPHA Comparison
GTE vs IPHA Comparison
Compare GTE & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- IPHA
- Stock Information
- Founded
- GTE 2003
- IPHA 1999
- Country
- GTE Canada
- IPHA France
- Employees
- GTE N/A
- IPHA N/A
- Industry
- GTE Oil & Gas Production
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- GTE Energy
- IPHA Health Care
- Exchange
- GTE Nasdaq
- IPHA Nasdaq
- Market Cap
- GTE 162.5M
- IPHA 160.1M
- IPO Year
- GTE N/A
- IPHA 2019
- Fundamental
- Price
- GTE $3.86
- IPHA $2.19
- Analyst Decision
- GTE
- IPHA Strong Buy
- Analyst Count
- GTE 0
- IPHA 1
- Target Price
- GTE N/A
- IPHA $11.00
- AVG Volume (30 Days)
- GTE 407.0K
- IPHA 12.6K
- Earning Date
- GTE 07-30-2025
- IPHA 09-11-2025
- Dividend Yield
- GTE N/A
- IPHA N/A
- EPS Growth
- GTE N/A
- IPHA N/A
- EPS
- GTE N/A
- IPHA N/A
- Revenue
- GTE $621,677,000.00
- IPHA $20,831,349.00
- Revenue This Year
- GTE $7.20
- IPHA $278.51
- Revenue Next Year
- GTE N/A
- IPHA $70.16
- P/E Ratio
- GTE N/A
- IPHA N/A
- Revenue Growth
- GTE N/A
- IPHA N/A
- 52 Week Low
- GTE $3.34
- IPHA $1.29
- 52 Week High
- GTE $8.78
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- GTE 38.57
- IPHA 59.91
- Support Level
- GTE $3.54
- IPHA $2.06
- Resistance Level
- GTE $4.14
- IPHA $2.28
- Average True Range (ATR)
- GTE 0.24
- IPHA 0.15
- MACD
- GTE -0.01
- IPHA 0.00
- Stochastic Oscillator
- GTE 28.07
- IPHA 33.03
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.